David A. Siegel Oncolytics Biotech Inc Transaction History

Two Sigma Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.85 - $1.59 $11,220 - $20,988	-13,200 Reduced 54.77%	10,900 $11,000
Q1 2022 May 16, 2022	SELL	$1.31 - $2.02 $23,711 - $36,562	-18,100 Reduced 42.89%	24,100 $38,000
Q4 2021 Feb 14, 2022	BUY	$1.39 - $2.3 $4,170 - $6,899	3,000 Added 7.65%	42,200 $59,000
Q3 2021 Nov 15, 2021	SELL	$1.93 - $2.77 $99,974 - $143,486	-51,800 Reduced 56.92%	39,200 $82,000
Q2 2021 Aug 16, 2021	SELL	$2.6 - $4.64 $4,940 - $8,816	-1,900 Reduced 2.05%	91,000 $252,000
Q1 2021 May 17, 2021	SELL	$2.32 - $4.11 $75,168 - $133,164	-32,400 Reduced 25.86%	92,900 $354,000
Q4 2020 Feb 16, 2021	BUY	$1.71 - $4.03 $5,643 - $13,299	3,300 Added 2.7%	125,300 $298,000
Q3 2020 Nov 16, 2020	SELL	$1.58 - $2.15 $38,078 - $51,815	-24,100 Reduced 16.5%	122,000 $206,000
Q2 2020 Aug 14, 2020	SELL	$1.33 - $2.76 $6,118 - $12,695	-4,600 Reduced 3.05%	146,100 $275,000
Q1 2020 May 15, 2020	BUY	$0.98 - $4.28 $147,686 - $644,996	150,700 New	150,700 $208,000

1.18M

Ticker ONCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,867,400
Market Cap $49.2M
Description
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.